This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeAbout AboutWhy PENBRAYA?Risks of Meningococcal DiseaseGaps in Vaccination CoverageDosing & Recommendations Effectiveness & Safety Effectiveness
& Safety ImmunogenicitySafety ProfileIn Your Practice In Your PracticeSimplified CombinationHow to Transition to PENBRAYAPreparing PENBRAYAResources ResourcesRequest a RepresentativeHealth Plan CoverageMaterialsVideos
Prescribing InformationIndicationsPatient SiteRequest a RepLoading
Although meningococcal disease is uncommon, it can lead to devastating consequences1-3While early symptoms can easily be mistaken for the flu, meningococcal disease can progress quickly and lead to long-term consequences or even death1,2,4Although meningococcal disease is uncommon, it can lead to devastating consequences1-3While early symptoms can easily be mistaken for the flu, meningococcal disease can progress quickly and lead to long-term consequences or even death1,2,4

Five serogroups of meningococcal bacteria (A, B, C, W, and Y) cause the majority of meningococcal disease6-11*

Five serogroups of meningococcal bacteria (A, B, C, W, and Y) cause the majority of meningococcal disease6-11*

ReferencesBased on data in the CDC enhanced meningococcal surveillance reports from 2017 to 2022 for 16- to 23-year-olds. The number of cases for each serogroup were as follows: MenA=0; MenB=120; MenC=20; MenW=5; MenY=9; other/unknown=31; and non-groupable=49.6-11CDC=Centers for Disease Control and Prevention.Quick links Icon of a hand with plus signs Why PENBRAYA?

PENBRAYA offers broad MenABCWY coverage in a single vaccine product

 Find out more LoadingIcon of an arrow hitting a target Immunogenicity

PENBRAYA elicited a robust immune response for serogroups A, B, C, W, and Y 

 See clinical data LoadingIcon of a hand with plus signs Gaps in Coverage

Disparities in meningococcal vaccination among adolescents contribute to gaps in coverage†

 Discover more LoadingAmong adolescents and young adults, those 16 through 23 years old have the highest rates of meningococcal disease.circle with hand icon Why PENBRAYA?

PENBRAYA offers the broadest MenABCWY protection in a single vaccine product

 Find out more Loadingcircle with target to represent immunogenicity Immunogenicity PENBRAYA elicited a robust immune response for serogroups A, B, C, W, and Y See clinical data Loadingcircle with hand icon Gaps in Coverage

Disparities in meningococcal vaccination among adolescents contribute to gaps in coverage

 Discover more LoadingAmong adolescents and young adults, those 16 through 23 years old have the highest rates of meningococcal disease.References: 1. World Health Organization. Meningitis. Published 2023. Accessed January 13, 2025. https://www.who.int/health-topics/meningitis#tab=tab_2 2. Centers for Disease Control and Prevention. Meningococcal disease: diagnosis, treatment, and complications. Last reviewed February 1, 2024. Accessed January 13, 2025. https://www.cdc.gov/meningococcal/about/diagnosis-treatment.html 3. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184-191. 4. Centers for Disease Control and Prevention. Meningococcal disease: Meningococcal disease symptoms and complications. Last reviewed August 20, 2024. Accessed April 28, 2025. https://www.cdc.gov/meningococcal/symptoms/index.html 5. Nadel S. Treatment of meningococcal disease. J Adolesc Health. 2016;59(suppl 2):S21-S28. 6. Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2017. Accessed April 28, 2025. https://stacks.cdc.gov/view/cdc/140464 7. Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2018. Accessed June 4, 2024. https://stacks.cdc.gov/view/cdc/111348 8. Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2019. Accessed January 13, 2025. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2019.pdf 9. Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2020. Accessed April 28, 2025. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2020.pdf 10. Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2021. Accessed April 28, 2025. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2021.pdf 11. Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2022. Accessed April 28, 2025. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2022-508.pdf 



To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-PBI-USA-0409
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-MCL-USA-0367
Indications
  • PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. PENBRAYA is approved for use in individuals 10 through 25 years of age
  • TRUMENBA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. TRUMENBA is approved for use in individuals 10 through 25 years of age 
Important Safety Information
  • Do not administer PENBRAYA or TRUMENBA to individuals with a history of severe allergic reaction (eg, anaphylaxis) to any component of PENBRAYA or TRUMENBA. Appropriate medical treatment used to manage allergic reactions must be available in the event an anaphylactic reaction occurs immediately following administration of PENBRAYA or TRUMENBA
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including PENBRAYA or TRUMENBA. Procedures should be in place to avoid injury from fainting
  • Some individuals with altered immunocompetence may have reduced immune responses to PENBRAYA or TRUMENBA
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by N. meningitidis groups A, B, C, W, and Y, even if they develop antibodies following vaccination with PENBRAYA
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by N. meningitidis group B, even if they develop antibodies following vaccination with TRUMENBA
  • Vaccination with PENBRAYA or TRUMENBA may not protect all vaccine recipients
  • Vaccination with PENBRAYA does not substitute for vaccination with a tetanus toxoid–containing vaccine to prevent tetanus
  • Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision by the healthcare professional to administer PENBRAYA to individuals with a history of GBS should take into account the expected benefits and potential risks 
  • For PENBRAYA, the most commonly reported (≥15%) solicited adverse reactions after Dose 1 and Dose 2, respectively, were pain at the injection site (89% and 84%), fatigue (52% and 48%), headache (47% and 40%), muscle pain (26% and 23%), injection site redness (26% and 23%), injection site swelling (25% and 24%), joint pain (20% and 18%), and chills (20% and 16%)
  • For TRUMENBA, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%)
  • Data are not available on the safety and effectiveness of using TRUMENBA and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • The safety and effectiveness of PENBRAYA or TRUMENBA have not been established in pregnant individuals
     
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for PENBRAYA and full Prescribing Information for TRUMENBA.Indications
  • PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. PENBRAYA is approved for use in individuals 10 through 25 years of age
  • TRUMENBA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. TRUMENBA is approved for use in individuals 10 through 25 years of age